Stockscreener 앱 받기
3.66
2.92%
-0.11
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada Therapeutics Inc Statistics – HAN:4E2 - TradingView
Basic earnings per share (basic EPS) of Relmada Therapeutics Inc – HAN:4E2 - TradingView
RELMADA THERAPEUTICS INC (RLMD) Stock Chart - ChartMill
Relmada Therapeutics Inc. (RLMD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Relmada Therapeutics, Inc.(NasdaqCM: RLMD) added to S&P Global BMI Index - marketscreener.com
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement - Seeking Alpha
RLMD Jumps As Executives Buy Shares And Signal Confidence - StocksToTrade
RLMD Jumps As Relmada Insider Buying Sparks Bullish Interest - StocksToTrade
RLMD Jumps As Relmada Insider Buying Sparks Bullish Focus - timothysykes.com
Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch - TipRanks
RELMADA THERAPEUTICS CFO Shenouda Maged Acquires 200,000 Shares at $4.20-$4.25 Range - Kalkine Media
Relmada Therapeutics (RLMD) CFO Maged Shenouda Buys 200,000 Shar - GuruFocus
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Relmada CEO Sergio Traversa buys 200,000 shares for $828,000 - Investing.com India
Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares - Investing.com
Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares By Investing.com - Investing.com India
Relmada Therapeutics Insiders Purchased Shares Worth Over $1.6M - TradingView
Relmada (NASDAQ: RLMD) CEO buys stock in two open-market trades - Stock Titan
Relmada Therapeutics (RLMD) CFO buys 200,000 shares in open market - Stock Titan
Relmada Therapeutics Announces Urology Chief Medical Officer Exit - TipRanks
RLMD Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Biotech Beats ConsensusEPS Growth Rate - dars.gov.et
Relmada Therapeutics (NASDAQ: RLMD) Announces Departure of CMO Dr. Raj S. Pruthi Effective September 3, 2026 - Kalkine Media
Relmada Therapeutics Inc. (RLMD) Key Financial Ratios – Valuation, Profitability & More - Value Research
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - The Manila Times
Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - Stock Titan
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD) - Yahoo Finance
Relmada Therapeutics Inc. (RLMD) Peer Comparison – Compare with Others - Value Research
Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures WeighAdvance Decline Line - vinanet.vn
Relmada Therapeutics (RLMD) Slips 0.87% as Shares Defend Support at $4.32Covered Call ETF - dars.gov.et
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Relmada (RLMD) Chart: Moves 0.54% Down to $4.61 in the Latest Session; Levels: Price Remains Between $4.38 Support and $4.84 Resistance on the DayATR Stop - dars.gov.et
Relmada (RLMD) Results Breakdown: The Bottom-Line Figure Beats Its Comparison on the Day; Share Response: Shares Move Lower 0.22% in the Latest ReadingCost Structure Review - vinanet.vn
H.C. Wainwright Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Relmada (RLMD) Q2 2026 Earnings Call Transcript - AOL.com
616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC - MarketBeat
Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds - Stock Titan
Relmada Therapeutics Earnings Call Highlights NDV-01 Path - TipRanks
Relmada Therapeutics Inc (RLMD) Stock Price, Trades & News - GuruFocus
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com UK
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround - Yahoo Finance
Equities Analysts Issue Forecasts for RLMD Q3 Earnings - marketbeat.com
Mizuho reiterates Relmada stock rating after manufacturing delay - Investing.com
Relmada Therapeutics (RLMD) Slides 7.6% to $4.57, Pressuring Key Support LevelPercent Above MA - dars.gov.et
Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
1.48%
0.31%
자본화:
|
볼륨(24시간):